1
|
Marra KV, Chen JS, Robles-Holmes HK, Miller J, Wei G, Aguilar E, Ideguchi Y, Ly KB, Prenner S, Erdogmus D, Ferrara N, Campbell JP, Friedlander M, Nudleman E. Development of a Semi-automated Computer-based Tool for the Quantification of Vascular Tortuosity in the Murine Retina. OPHTHALMOLOGY SCIENCE 2024; 4:100439. [PMID: 38361912 PMCID: PMC10867761 DOI: 10.1016/j.xops.2023.100439] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 12/19/2022] [Revised: 10/10/2023] [Accepted: 11/27/2023] [Indexed: 02/17/2024]
Abstract
Purpose The murine oxygen-induced retinopathy (OIR) model is one of the most widely used animal models of ischemic retinopathy, mimicking hallmark pathophysiology of initial vaso-obliteration (VO) resulting in ischemia that drives neovascularization (NV). In addition to NV and VO, human ischemic retinopathies, including retinopathy of prematurity (ROP), are characterized by increased vascular tortuosity. Vascular tortuosity is an indicator of disease severity, need to treat, and treatment response in ROP. Current literature investigating novel therapeutics in the OIR model often report their effects on NV and VO, and measurements of vascular tortuosity are less commonly performed. No standardized quantification of vascular tortuosity exists to date despite this metric's relevance to human disease. This proof-of-concept study aimed to apply a previously published semi-automated computer-based image analysis approach (iROP-Assist) to develop a new tool to quantify vascular tortuosity in mouse models. Design Experimental study. Subjects C57BL/6J mice subjected to the OIR model. Methods In a pilot study, vasculature was manually segmented on flat-mount images of OIR and normoxic (NOX) mice retinas and segmentations were analyzed with iROP-Assist to quantify vascular tortuosity metrics. In a large cohort of age-matched (postnatal day 12 [P12], P17, P25) NOX and OIR mice retinas, NV, VO, and vascular tortuosity were quantified and compared. In a third experiment, vascular tortuosity in OIR mice retinas was quantified on P17 following intravitreal injection with anti-VEGF (aflibercept) or Immunoglobulin G isotype control on P12. Main Outcome Measures Vascular tortuosity. Results Cumulative tortuosity index was the best metric produced by iROP-Assist for discriminating between OIR mice and NOX controls. Increased vascular tortuosity correlated with disease activity in OIR. Treatment of OIR mice with aflibercept rescued vascular tortuosity. Conclusions Vascular tortuosity is a quantifiable feature of the OIR model that correlates with disease severity and may be quickly and accurately quantified using the iROP-Assist algorithm. Financial Disclosures Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Collapse
Affiliation(s)
- Kyle V. Marra
- Department of Molecular Medicine, The Scripps Research Institute, San Diego, California
- School of Medicine, University of California San Diego, San Diego, California
| | - Jimmy S. Chen
- Department of Ophthalmology, Shiley Eye Institute, University of California San Diego, San Diego, California
| | - Hailey K. Robles-Holmes
- Department of Ophthalmology, Shiley Eye Institute, University of California San Diego, San Diego, California
| | - Joseph Miller
- Department of Ophthalmology, Shiley Eye Institute, University of California San Diego, San Diego, California
| | - Guoqin Wei
- Department of Molecular Medicine, The Scripps Research Institute, San Diego, California
| | - Edith Aguilar
- Department of Molecular Medicine, The Scripps Research Institute, San Diego, California
| | - Yoichiro Ideguchi
- Department of Molecular Medicine, The Scripps Research Institute, San Diego, California
| | - Kristine B. Ly
- College of Optometry, Pacific University, Forest Grove, Oregon
| | - Sofia Prenner
- Department of Ophthalmology, Shiley Eye Institute, University of California San Diego, San Diego, California
| | - Deniz Erdogmus
- Department of Electrical and Computer Engineering, Northeastern University, Boston, Massachusetts
| | - Napoleone Ferrara
- Department of Ophthalmology, Shiley Eye Institute, University of California San Diego, San Diego, California
| | - J. Peter Campbell
- Department of Ophthalmology, Casey Eye Institute, Oregon Health & Science University, Portland, Oregon
| | - Martin Friedlander
- Department of Molecular Medicine, The Scripps Research Institute, San Diego, California
| | - Eric Nudleman
- Department of Ophthalmology, Shiley Eye Institute, University of California San Diego, San Diego, California
| |
Collapse
|
2
|
Li L, Zhu M, Wu W, Qin B, Gu J, Tu Y, Chen J, Liu D, Shi Y, Liu X, Sang A, Ding D. Brivanib, a multitargeted small‐molecule tyrosine kinase inhibitor, suppresses laser‐induced CNV in a mouse model of neovascular AMD. J Cell Physiol 2019; 235:1259-1273. [PMID: 31270802 DOI: 10.1002/jcp.29041] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2019] [Accepted: 06/12/2019] [Indexed: 12/13/2022]
Affiliation(s)
- Lele Li
- Department of Ophthalmology Affiliated Hospital of Nantong University Nantong Jiangsu China
| | - Manhui Zhu
- Department of Ophthalmology Lixiang Eye Hospital of Soochow University Suzhou Jiangsu China
| | - Wenli Wu
- Medical College Nantong University Nantong Jiangsu China
| | - Bai Qin
- Department of Ophthalmology Affiliated Hospital of Nantong University Nantong Jiangsu China
| | - Jiayi Gu
- Department of Ophthalmology Affiliated Hospital of Nantong University Nantong Jiangsu China
| | - Yuanyuan Tu
- Department of Ophthalmology Affiliated Hospital of Nantong University Nantong Jiangsu China
| | - Jianing Chen
- Medical College Nantong University Nantong Jiangsu China
| | - Dong Liu
- Co‐innovation Center of Neuroregeneration, Jiangsu Key Laboratory of Neuroregeneration Nantong University Nantong China
| | - Yunwei Shi
- Co‐innovation Center of Neuroregeneration, Jiangsu Key Laboratory of Neuroregeneration Nantong University Nantong China
| | - Xiaojuan Liu
- Department of Pathogen Biology, Medical College Nantong University Nantong Jiangsu China
| | - Aimin Sang
- Department of Ophthalmology Affiliated Hospital of Nantong University Nantong Jiangsu China
| | - Dongmei Ding
- Department of Ophthalmology Laizhou City People's Hospital Yantai Shandong China
| |
Collapse
|
3
|
Ramazani F, Hiemstra C, Steendam R, Kazazi-Hyseni F, Van Nostrum C, Storm G, Kiessling F, Lammers T, Hennink W, Kok R. Sunitinib microspheres based on [PDLLA-PEG-PDLLA]-b-PLLA multi-block copolymers for ocular drug delivery. Eur J Pharm Biopharm 2015; 95:368-77. [DOI: 10.1016/j.ejpb.2015.02.011] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2014] [Revised: 02/05/2015] [Accepted: 02/09/2015] [Indexed: 10/24/2022]
|
4
|
Scott A, Powner MB, Fruttiger M. Quantification of vascular tortuosity as an early outcome measure in oxygen induced retinopathy (OIR). Exp Eye Res 2014; 120:55-60. [PMID: 24418725 DOI: 10.1016/j.exer.2013.12.020] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2013] [Revised: 12/11/2013] [Accepted: 12/30/2013] [Indexed: 12/19/2022]
Abstract
Oxygen-induced retinopathy (OIR) in mice is a popular model system to study pathological angiogenesis in the retinal vasculature. The system is based on vessel depletion by exposure to hyperoxia, which results in acute retinal hypoxia upon return to room air. This hypoxia then triggers neovascularization in the remaining vessels after 5 days. Here we aimed to establish an additional and earlier experimental readout of the vascular response to hypoxia by quantifying the tortuosity of retinal arteries after 2 days. Mouse pups from three different mouse strains were exposed to hyperoxia from postnatal day (P) 7 to P12 and retinas were analysed at P12, P14 and P17. Hypoxia was assessed by staining with the hypoxia marker EF5 and by measuring Vegf mRNA by qPCR. The retinal vasculature was stained in whole mount retinas and tortuosity of radial arterioles was quantified. C57BL/6J mice were used because the vascular response at P17 is well characterised in this strain. We also used C3H/HeJ mice, which contain the retinal degeneration 1 (Rd1) mutation (Pde6b(Rd1)) and have abnormally thin retinas. These thinner, C3H/HeJ retinas do not become ischemic during the OIR model and do not develop neovascularization. They can therefore be used as a control. In addition, we included C3H/HeJ mice that lack the Rd1 mutation (C3H/He(Rd1-)), with normal thickness retinas, to control for strain differences between C57BL/6J and C3H/HeJ. Quantification of vessel tortuosity at P14 showed tortuous arteries in normal thickness retinas (C57BL/6J and C3H/He(Rd1-)) and straight arteries in the thin C3H/HeJ retinas. This correlated with hypoxia, which was severe in normal thickness retinas and mild in the thin C3H/HeJ retinas. Furthermore, at P17 the normal thickness retinas showed strong neovascularisation whereas in the thin C3H/HeJ retinas the retinal vasculature regenerated normally. In conclusion we have demonstrated that arterial tortuosity can act as an early readout for hypoxia in the OIR model before neovascularisation develops.
Collapse
Affiliation(s)
- Andrew Scott
- UCL Institute of Ophthalmology, University College London, 11-43 Bath Street, London EC1V 9EL, UK
| | - Michael B Powner
- UCL Institute of Ophthalmology, University College London, 11-43 Bath Street, London EC1V 9EL, UK
| | - Marcus Fruttiger
- UCL Institute of Ophthalmology, University College London, 11-43 Bath Street, London EC1V 9EL, UK.
| |
Collapse
|
5
|
Reynolds AL, Kent D, Kennedy BN. Current and Emerging Therapies for Ocular Neovascularisation. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2014; 801:797-804. [DOI: 10.1007/978-1-4614-3209-8_100] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
6
|
Zhang H, Sun N, Liang H, Xiao X, Liu X, Wang Y. The protective effect of 17 beta-estradiol on oxygen-induced retinopathy and its relation with the changes of malondialdehyde. J Biomed Res 2013; 24:138-44. [PMID: 23554624 PMCID: PMC3596548 DOI: 10.1016/s1674-8301(10)60022-x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2009] [Indexed: 01/31/2023] Open
Abstract
Objective Retinopathy of prematurity is becoming obvious with the improvement of neonatal ambulance. However there is still not a good treatment. The present study is to observe the effect of 17 beta-estradiol (E2) on oxygen-induced retinopathy (OIR), and explore the relationship between the changes of avascular area and malondialdehyde (MDA) in retina. Methods Newborn oxygen-exposed mice underwent subcutaneous injections of different dose of E2 (0.1 µg, 1.0 µg, 10.0 µg ), tamoxifen or phosphate buffered saline (PBS; controls)everyday from post-natal day (p)7 to p17. At p17, retinal flat mounts were scored for the percentage of avascular/total retinal area, and pathological changes during revascularization. The MDA concentration in the retina was determined also. In the most efficacious E2 group (10.0 µg), 100.0 µg tamoxifen was also administered, and the percentage of capillary-free/total retinal area determined, and the retinal malondialdehyde concentration assayed. Results The mean percentage of capillary-free area over total retinal area was 0(PBS, in room air), 34.197±1.301(PBS, in hyperoxia), 23.685±0.407 (0.1 µg E2), 14.648±0.355 (1.0 µg E2), 4.693±0.450 (10.0 µg E2) and 32.240±0.654 (10.0 µg E2 +100.0 µg tamoxifen). The difference was significant (F = 2778.759, P < 0.01), and the difference between any two groups were also significant (all P value were less than 0.01). The predilection of tufts and clusters during revascularization was mainly aggregated in zones 2 and 3, but the difference of retinal neovascular clusters and tufts in fourth zone among different groups were significant [clusters (F = 44.719, P < 0.01) vs tufts (F = 39.997, P < 0.01)]. The mean MDA concentration were 0.711±0.037(PBS, in room air), 2.084±0.066 (PBS, in hyperoxia), 1.829±0.091(0.1 µg E2), 1.152±0.067(1.0 µg E2), 0.796±0.027(10.0 µg E2), 1.988±0.049(10.0 µg E2 +100.0 µg tamoxifen) (F = 628.103, P < 0.01). The difference between any two groups were also significant (all P value were less than 0.05). The close relation between the percentage of avascular/total retinal area and MDA concentration was also verified (r = 0.981, P < 0.01). Conclusion Oxidative stress responses play a pivotal role in OIR, by means of receptor pathway. E2 can alleviate oxidative stress reaction, and thus ameliorate the severity of oxygen induced retinopathy.
Collapse
Affiliation(s)
- Hongbing Zhang
- Department of Ophthalmology, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi Province 710004, China. ; Eye Institute of Shaanxi Province and Xi'an Eye Hospital, Xi'an, Shaanxi Province 710002, China
| | | | | | | | | | | |
Collapse
|
7
|
Barak Y, Heroman WJ, Tezel TH. The past, present, and future of exudative age-related macular degeneration treatment. Middle East Afr J Ophthalmol 2012; 19:43-51. [PMID: 22346114 PMCID: PMC3277024 DOI: 10.4103/0974-9233.92115] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Treatment of exudative age-related macular degeneration has been revolutionized within the last 6 years with the introduction of vascular endothelial growth factor neutralizing agents. Previously popular “destructive treatments,” such as laser photocoagulation and photodynamic treatment have either been abandoned or used as an adjunct to pharmacotherapy. Despite the increase in vision after antivascular endothelial growth factor (VEGF) agents, they require repetitive and costly intravitreal injections that also carry the inherit risks of infection, retinal tears, and detachment. Several new and more potent VEGF inhibitors are at different stages of development. The goal of evolving pharmacotherapy is to preserve the therapeutic effect while reducing or eliminating the discomfort of intravitreal drug delivery, as well as identify new therapeutic targets. Complement inhibitors, immunomodulators, integrin inhibitors are a few of the new class of drugs that are expected to be in our armamentarium soon. Current medications act to decrease leakage through abnormal subretinal choroidal vasculature and promote involution. However, these medications are only effective in treating the active stage of the choroidal neovascular membrane. Restoration of vision of a large number of patients with involuted choroidal neovascular membranes is warranted. For this purpose, tissue engineering techniques have been employed to reconstruct the subretinal anatomy. Discovery of biomarkers, pharmacogenetics, and very specific targeting holds the promise of increased potency and safety in the future.
Collapse
Affiliation(s)
- Yoreh Barak
- Department of Ophthalmology and Visual Sciences, Kentucky Lions Eye Center, University of Louisville School of Medicine, Louisville, KY, USA
| | | | | |
Collapse
|
8
|
Vadlapudi AD, Patel A, Cholkar K, Mitra AK. Recent Patents on Emerging Therapeutics for the Treatment of Glaucoma, Age Related Macular Degeneration and Uveitis. RECENT PATENTS ON BIOMEDICAL ENGINEERING 2012; 5:83-101. [PMID: 25414810 PMCID: PMC4235159 DOI: 10.2174/1874764711205010083] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Advancements in the field and rising interest among pharmaceutical researchers have led to the development of new molecules with enhanced therapeutic activity. Design of new drugs which can target a particular pathway and/or explore novel targets is of immense interest to ocular pharmacologists worldwide. Delivery of suitable pharmacologically active agents at proper dose (within the therapeutic window) to the target tissues without any toxicity to the healthy ocular tissues still remain an elusive task. Moreover, the presence of static and dynamic barriers to drug absorption including the corneal epithelium (lipophilic), corneal and scleral stroma (hydrophilic), conjunctival lymphatics, choroidal vasculature and the blood-ocular barriers also pose a significant challenge for achieving therapeutic drug concentrations at the target site. Although many agents are currently available, new compounds are being introduced for treating various ocular diseases. Deeper understanding of the etiology and complex mechanisms associated with the disease condition would aid in the development of potential therapeutic candidates. Novel small molecules as well as complex biotechnology derived macromolecules with superior efficacy, safety and tolerability are being developed. Therefore, this review article provides an overview of existing drugs, treatment options, advances in emerging therapeutics and related recent patents for the treatment of ocular disorders such as glaucoma, age related macular degeneration (AMD) and uveitis.
Collapse
Affiliation(s)
- Aswani Dutt Vadlapudi
- Division of Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, 2464 Charlotte Street, Kansas City, MO 64108-2718, USA
| | - Ashaben Patel
- Division of Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, 2464 Charlotte Street, Kansas City, MO 64108-2718, USA
| | - Kishore Cholkar
- Division of Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, 2464 Charlotte Street, Kansas City, MO 64108-2718, USA
| | - Ashim K. Mitra
- Division of Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, 2464 Charlotte Street, Kansas City, MO 64108-2718, USA
| |
Collapse
|
9
|
Emerson MV, Lauer AK. Current and emerging therapies for the treatment of age-related macular degeneration. Clin Ophthalmol 2011; 2:377-88. [PMID: 19668729 PMCID: PMC2693977 DOI: 10.2147/opth.s1485] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Age-related macular degeneration (AMD) is the leading cause of vision loss in the industrialized world. In the last few decades, the mainstay of treatment for choroidal neovascularization (CNV) due to AMD has been thermal laser photocoagulation. In the last decade, photodynamic therapy with verteporfin extended treatment for more patients. While both of these treatments have prevented further vision loss in a subset of patients, improvement in visual acuity is rare. Anti-vascular endothelial growth factor A (VEGF) therapy has revolutionized the treatment of AMD-related CNV. Pegaptanib, an anti-VEGF aptamer prevents vision loss in CNV, although the performance is similar to that of photodynamic therapy. Ranibizumab, an antibody fragment and bevacizumab, a full-length humanized monoclonal antibody against VEGF have both shown promising results with improvements in visual acuity with either agent. VEGF trap, a modified soluble VEGF receptor analogue, binds VEGF more tightly than all other anti-VEGF agents and has also shown promising results in early trials. Other treatment strategies to decrease the effect of VEGF have used small interfering ribonucleic acid (RNA) to inhibit VEGF production and VEGF receptor production. Steroids, including anecortave acetate in the treatment and prevention of CNV, have shown promise in controlled trials. Receptor tyrosine kinase inhibitors, such as vatalanib, inhibit downstream effects of VEGF, and have been effective in the treatment of CNV in early studies. Squalamine lactate inhibits plasma membrane ion channels with downstream effects on VEGF, and has shown promising results with systemic administration. Other growth factors, including pigment epithelium-derived growth factor that has been administered via an adenoviral vector has shown promising initial results. In some patients ciliary neurotrophic factor is currently being studied for the inhibition of progression of geographic atrophy. Combination therapy has been investigated, and may prove to be more effective in the management of AMD-associated CNV. Ongoing and future studies will be crucial for optimizing the treatment of patients with AMD.
Collapse
Affiliation(s)
- M Vaughn Emerson
- Casey Eye Institute, Oregon Health and Science University, Portland, OR, USA
| | | |
Collapse
|
10
|
Schiffelers RM, van der Vaart TK, Storm G. Neovascular age-related macular degeneration: opportunities for development of first-in-class biopharmaceuticals. BioDrugs 2011; 25:171-89. [PMID: 21627341 DOI: 10.2165/11589330-000000000-00000] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
Age-related macular degeneration (AMD) is a condition that may cause blindness. The prevalence of the disease in the Western world is estimated at 1-2% of the population. Over the past decade, treatment of neovascular AMD has been shifting from destruction of newly formed blood vessels towards inhibitors that silence the vascular endothelial growth factor (VEGF) pathway. Such agents are often first-in-class biopharmaceuticals that benefit from the fact that they can be locally administered in an immune-privileged environment with slow clearance. These new VEGF pathway inhibitors have improved therapeutic effects over conventional treatment and have promoted the identification of novel targets for inhibition of AMD angiogenesis. This review describes the rationale behind the shift from conventional to current treatment options and discusses investigational, most notably biopharmaceutical, drugs that are in clinical trials. It also provides possible points for improvement of these treatments, specifically regarding their delivery.
Collapse
Affiliation(s)
- Raymond M Schiffelers
- Division of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, the Netherlands.
| | | | | |
Collapse
|
11
|
Ehlken C, Martin G, Lange C, Gogaki EG, Fiedler U, Schaffner F, Hansen LL, Augustin HG, Agostini HT. Therapeutic interference with EphrinB2 signalling inhibits oxygen-induced angioproliferative retinopathy. Acta Ophthalmol 2011; 89:82-90. [PMID: 19764912 DOI: 10.1111/j.1755-3768.2009.01609.x] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
PURPOSE To investigate whether EphrinB2 (EfnB2) or EphB4 influence retinal angiogenesis under physiological or pathological conditions. METHODS Using the mouse model of oxygen-induced proliferative retinopathy (OIR), the expression of EfnB2, EphB4, vascular endothelial growth factor (VEGF), VEGFR1 and VEGFR2 was quantified by quantitative polymerase chain reaction (qPCR) and localized in EfnB2- and EphB4-lacZ mice. Angioproliferative retinopathy was manipulated by intravitreal injection of dimeric EfnB2 and monomeric or dimeric EphB4. RESULTS Dimeric EphB4 (EphB4-Fc) and EfnB2 (EfnB2-Fc) enhanced hypoxia-induced angioproliferative retinopathy but not physiological angiogenesis. Monomeric EphB4 (sEphB4) reduced angiogenesis. The messenger RNA (mRNA) level of EfnB2 increased significantly in the hyperoxic phase (P7-P12), while EphB4, VEGF, VEGFR1 and VEGFR2 showed a significant - up to fivefold - increased expression at P14, the start of morphologically visible vasoproliferation caused by relative hypoxia. CONCLUSION The ephrin/Eph system is involved in angioproliferative retinopathy. Stimulation of EphB4 and EfnB2 signalling using EfnB2-Fc and EphB4-Fc, respectively, enhanced hypoxia-induced angiogenesis. In contrast, sEphB4 inhibited hypoxia-induced angiogenesis. Therefore, angiogenesis is enhanced by signalling through both EphB4 (forward) and EfnB2 (reverse). The distinction in the expression kinetics of EphB4 and EfnB2 indicates that they govern two different signalling pathways and are regulated in diverse ways. sEphB4 might be a useful drug for antiangiogenic therapy.
Collapse
|
12
|
Giuliari GP, Guel DA, Cortez MA, Cortez RT. Selective and pan-blockade agents in the anti-angiogenic treatment of proliferative diabetic retinopathy: a literature summary. Can J Ophthalmol 2010; 45:501-8. [PMID: 20648074 DOI: 10.3129/i10-023] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]
Abstract
Diabetes mellitus is a major health concern in the modern world. Several sight-threatening ocular conditions are included in the array of health problems associated with this disease. Understandably, 2 of the more sight-threatening problems, proliferative diabetic retinopathy (PDR) and diabetic macular edema (DME), have received a great deal of attention in recent years. Pivotal studies, such as the Early Treatment Diabetic Retinopathy Study and the Diabetic Retinopathy Study, have established laser photocoagulation as the accepted treatment modality. The last decade has seen a surge in clinical data supporting the use of pharmacologic therapy in place of the often damaging laser therapy. Supporting data are based on the establishment of vascular endothelial growth factor (VEGF) as a key facilitator of disease progression in diabetic retinopathy. We will discuss the advantages and disadvantages of both selective and pan-blockade anti-VEGF agents available today in an effort to help guide physicians wishing to use these agents to treat PDR and DME.
Collapse
|
13
|
Barakat MR, Kaiser PK. VEGF inhibitors for the treatment of neovascular age-related macular degeneration. Expert Opin Investig Drugs 2010; 18:637-46. [PMID: 19388880 DOI: 10.1517/13543780902855316] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Age-related macular degeneration (AMD) is the leading cause of blindness in the Western world for those patients aged 50 years or older. Neovascular AMD, a subtype characterized by the growth of new, pathologic blood vessels, results in most of the cases of severe and rapid vision loss associated with AMD. A critical activator of angiogenesis in neovascular AMD is VEGF. Several therapies have been and are now being developed for neovascular AMD, with the goal of inhibiting VEGF. These VEGF inhibitors include the RNA aptamer pegaptanib, partial and full-length antibodies ranibizumab and bevacizumab, VEGF receptor decoy VEGF Trap, small interfering RNA-based therapies bevasiranib and AGN211745, sirolimus, and tyrosine kinase inhibitors including vatalanib, pazopanib, TG100801, TG101095, AG013958 and AL39324. At present, established therapies have met with great success in reducing the vision loss associated with neovascular AMD, whereas those still investigational in nature offer the potential for further advances.
Collapse
Affiliation(s)
- Mark Rami Barakat
- Cole Eye Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA.
| | | |
Collapse
|
14
|
Kinetics of retinal vaso-obliteration and neovascularisation in the oxygen-induced retinopathy (OIR) mouse model. Graefes Arch Clin Exp Ophthalmol 2009; 247:1205-11. [DOI: 10.1007/s00417-009-1116-4] [Citation(s) in RCA: 47] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2009] [Revised: 04/09/2009] [Accepted: 05/19/2009] [Indexed: 12/20/2022] Open
|
15
|
Abstract
Age-related macular degeneration (AMD) affects an estimated 14 million people worldwide, and is the leading cause of severe, irreversible vision loss in individuals over the age of 50 years in Western societies. Choroidal neovascularization (CNV), the hallmark of 'wet', 'exudative' or 'neovascular' AMD, is responsible for approximately 90% of cases of severe vision loss due to AMD. Vascular endothelial growth factor (VEGF) has been shown to play a key role in the regulation of CNV and vascular permeability. Ranibizumab, the current gold standard in the US for the treatment of neovascular AMD, exerts its effect through binding and inhibition of all isoforms of VEGF. Randomized controlled clinical trials have established ranibizumab as the first US FDA-approved therapy for neovascular AMD to result in improvement in visual acuity. Despite impressive outcomes, treatment with ranibizumab requires sustained treatment regimens and frequent intravitreal injections. In this review, we discuss promising emerging therapies for neovascular AMD that aim to improve outcomes, safety and treatment burden through novel mechanisms of action. Currently in phase III clinical trials, VEGF Trap is a receptor decoy that targets VEGF with higher affinity than ranibizumab and other currently available anti-VEGF agents. Another promising therapeutic strategy is the blockade of VEGF effects by inhibition of the tyrosine kinase cascade downstream from the VEGF receptor; such therapies currently in development include vatalanib, TG100801, pazopanib, AG013958 and AL39324. Small interfering RNA technology-based therapies have been designed to downregulate the production of VEGF (bevasiranib) or VEGF receptors (AGN211745) by degradation of specific messenger RNA. Other potential therapies include pigment epithelium-derived factor-based therapies, nicotinic acetylcholine receptor antagonists, integrin antagonists and sirolimus.
Collapse
Affiliation(s)
- Aimee V Chappelow
- Cole Eye Institute, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
| | | |
Collapse
|
16
|
Berdugo Polak M, Behar-Cohen F. Dégénérescence maculaire liée à l’âge exsudative : efficacité et limites des différents traitements. J Fr Ophtalmol 2008; 31:537-56. [DOI: 10.1016/s0181-5512(08)72475-6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
17
|
Gamulescu MA, Helbig H. A new era in the treatment of age-related macular degeneration: from Factor X to antiangiogenesis. Expert Opin Ther Pat 2007. [DOI: 10.1517/13543776.17.11.1351] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
|
18
|
Lange C, Ehlken C, Martin G, Konzok K, Moscoso Del Prado J, Hansen LL, Agostini HT. Intravitreal injection of the heparin analog 5-amino-2-naphthalenesulfonate reduces retinal neovascularization in mice. Exp Eye Res 2007; 85:323-7. [PMID: 17662276 DOI: 10.1016/j.exer.2007.05.007] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2006] [Revised: 05/29/2007] [Accepted: 05/30/2007] [Indexed: 11/16/2022]
Abstract
The effect of the heparin analog 5-amino-2-naphthalenesulfonate (5-amino-2-NMS) on retinal neovascularization was investigated in the mouse model for oxygen-induced retinopathy (OIR). From postnatal day 7 (P7) until P12, mice were kept in a 75% oxygen environment. On P12, they received an intravitreal injection of 10mM 5-amino-2-NMS in one eye and PBS as control substance in the fellow eye. The animals were intracardially perfused with fluorescein-dextran solution on P17. Retinal whole mounts were prepared and ischemic retinopathy was evaluated in 30 animals using a standardized retinopathy score. A single intravitreal injection of 5-amino-2-NMS reduces significantly angioproliferative changes (blood vessel tufts, extra-retinal neovascularization, and blood vessel tortuosity) compared to the contralateral control eye (p=0.025). The median retinopathy score (maximal 13) for the 5-amino-2-NMS treated eyes was 6 versus 8 for the control eyes. 5-Amino-2-NMS binds to the heparin-binding site of FGF1 and FGF2 and thus may be a promising substance for the local treatment of retinal neovascularization.
Collapse
Affiliation(s)
- Clemens Lange
- Augenklinik, Universitätsklinikum Freiburg, Killianstrasse 5, 79106 Freiburg, Germany
| | | | | | | | | | | | | |
Collapse
|
19
|
McAvoy CE, Chakravarthy U. VEGF inhibition: latest developments. EXPERT REVIEW OF OPHTHALMOLOGY 2007. [DOI: 10.1586/17469899.2.4.621] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
20
|
Abstract
Age-related macular degeneration (AMD) is the leading cause of adult blindness among individuals aged 50 and older in the Western world, with the neovascular form of AMD responsible for the most severe and rapid visual loss. Although monotherapy with currently available treatments can slow the rate of loss of vision in eyes with neovascular AMD, they do not significantly improve vision. Vascular endothelial growth factor-A (VEGF-A) plays a critical role in the pathogenesis of neovascular AMD, and ranibizumab is a promising new treatment that targets all VEGF-A isoforms and their biologically active degradation products. Clinical trials have reported that ranibizumab treatment resulted in greater proportions of patients achieving a < 15 letter loss of visual acuity and improved vision at 12 and 24 months than control groups. The incidence of serious ocular and systemic adverse events was low in all ranibizumab trials to date. Currently, ranibizumab is the only treatment for neovascular AMD to demonstrate significant improvement in vision for many patients and represents a major advance in treating neovascular AMD.
Collapse
Affiliation(s)
- P K Kaiser
- Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, OH, USA
| | | |
Collapse
|
21
|
Emerson MV, Lauer AK. Emerging Therapies for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema. BioDrugs 2007; 21:245-57. [PMID: 17628122 DOI: 10.2165/00063030-200721040-00005] [Citation(s) in RCA: 55] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Diabetic macular edema (DME) and choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD) are the leading causes of vision loss in the industrialized world. The mainstay of treatment for both conditions has been thermal laser photocoagulation, while there have been recent advances in the treatment of CNV using photodynamic therapy with verteporfin. While both of these treatments have prevented further vision loss in a subset of patients, vision improvement is rare. Anti-vascular endothelial growth factor (VEGF)-A therapy has revolutionized the treatment of both conditions. Pegaptanib, an anti-VEGF aptamer, prevents vision loss in CNV, although the performance is similar to that of photodynamic therapy. Ranibizumab, an antibody fragment, and bevacizumab, a full-length humanized monoclonal antibody against VEGF, have both shown promising results, with improvements in visual acuity in the treatment of both diseases. VEGF trap, a modified soluble VEGF receptor analog, binds VEGF more tightly than all other anti-VEGF therapies, and has also shown promising results in early trials. Other treatment strategies to decrease the effect of VEGF have used small interfering RNA to inhibit VEGF production and VEGF receptor production. Corticosteroids have shown efficacy in controlled trials, including anacortave acetate in the treatment and prevention of CNV, and intravitreal triamcinolone acetonide and the fluocinolone acetonide implant in the treatment of DME. Receptor tyrosine kinase inhibitors, such as vatalanib, inhibit downstream effects of VEGF, and have been effective in the treatment of CNV in early studies. Squalamine lactate inhibits plasma membrane ion channels with downstream effects on VEGF, and has shown promising results with systemic administration. Initial results are also encouraging for other growth factors, including pigment epithelium-derived factor administered via an adenoviral vector. Ruboxistaurin, which decreases protein kinase C activity, has shown positive results in the prevention of diabetic retinopathy progression, and the resolution of DME. Combination therapy has been investigated, and may prove to be quite effective in the management of both DME and AMD-associated CNV, although ongoing and future studies will be crucial to treatment optimization for each condition.
Collapse
Affiliation(s)
- M Vaughn Emerson
- Casey Eye Institute, Oregon Health and Science University, Portland, Oregon 97239-4197, USA
| | | |
Collapse
|
22
|
Bhisitkul RB. Vascular endothelial growth factor biology: clinical implications for ocular treatments. Br J Ophthalmol 2006; 90:1542-7. [PMID: 17114590 PMCID: PMC1857529 DOI: 10.1136/bjo.2006.098426] [Citation(s) in RCA: 122] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Decades of research on vascular endothelial growth factor (VEGF) have reached fruition with the recent development of intravitreal anti-VEGF treatments for exudative age-related macular degeneration. VEGF is a critical regulator of angiogenesis and vascular permeability with diverse roles, both pathological and physiological, during development and adulthood. The aim of this article is to review aspects of VEGF biology that may be relevant to the clinical use of anti-VEGF agents in ophthalmology: molecular characteristics and isoforms of VEGF; its roles in vasculogenesis, vascular maintenance and angiogenesis; systemic effects of VEGF inhibition; and properties of current anti-VEGF agents.
Collapse
Affiliation(s)
- R B Bhisitkul
- Department of Ophthalmology, Beckman Vision Center, University of California San Francisco, 10 Koret Way, K301, San Francisco, CA 94143, USA.
| |
Collapse
|
23
|
Kaiser PK. Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases. Am J Ophthalmol 2006; 142:660-8. [PMID: 17011860 DOI: 10.1016/j.ajo.2006.05.061] [Citation(s) in RCA: 107] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2006] [Revised: 05/16/2006] [Accepted: 06/01/2006] [Indexed: 11/24/2022]
Abstract
PURPOSE To provide an overview of angiogenesis and vascular endothelial growth factor (VEGF) and discusses the development approach, safety, and efficacy results of current and emerging anti-VEGF therapies for ocular diseases. DESIGN Analysis of literature and current clinical trials of antiangiogenic agents for age-related macular degeneration (AMD). METHODS Literature review. RESULTS There are several novel antiangiogenic molecules that target vascular endothelial growth factor and are being used in the management of AMD. Large scale, Phase III trials have shown promising results in improving vision in this devastating disease. CONCLUSIONS Therapies that target VEGF have shown tremendous promise as treatments for AMD.
Collapse
|